Significant impact of survivin on myeloma cell growth

Leukemia

Volumn 21, Issue 5, 2007, Pages 1070-1078

  Romagnoli, M ^a   Trichet, V ^a   David, C ^a   Clement M ^a   Moreau, P ^a   Bataille, R ^a   Barille Nion S ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SHORT HAIRPIN RNA; SURVIVIN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN TARGETING; RNA INTERFERENCE;

EID: 34247577611     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404602     Document Type: Article

References (41)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100 57-70.
2. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22: 8581-8589.
3. Li F. Survivin study: What is the next wave? J Cell Physiol 2003; 197: 8-29.
4. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 2006; 18: 609-615.
5. Liston P, Fong WG, Korneluk RG. The inhibitors of apoptosis: There is more to life than Bcl2. Oncogene 2003; 22: 8568-8580.
6. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
7. Chen-Kiang S. Cell-cycle control of plasma cell differentiation and tumorigenesis. Immunol Rev 2003; 194: 39-47.
8. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002; 99: 1745-1757.
9. Specht K, Haralambieva E, Bink K, Kremer M, Mandl-Weber S, Koch I et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood 2004; 104: 1120-1126.
10. Magrangeas F, Lode L, Wuilleme S, Minvielle S, Avet-Loiseau H. Genetic heterogeneity in multiple myeloma. Leukemia 2005; 19: 191-194.
11. Chng WJ, Ahmann GJ, Henderson K, Santana-Davila R, Greipp PR, Gertz MA et al. Clinical implication of centrosome amplification in plasma cell neoplasm. Blood 2006; 107: 3669-3675.
12. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L is an essential survival protein of human myeloma cells. Blood 2002; 100: 194-199.
13. Kardosh A, Soriano N, Liu YT, Uddin J, Petasis NA, Hofman FM et al. Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood 2005; 106: 4330-4338.
14. Stromberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, Axelson M et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 2006; 107: 669-678.
15. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: Therapeutic applications. Blood 2002; 99: 4079-4086.
16. Bataille R, Jégo G, Robillard N, Barillé-Nion S, Harousseau JL, Moreau P et al. The phenotype of normal, reactive and malignant plasma cells. Identification of 'many and multiple myelomas' and of new targets for myeloma therapy. Hematologica 2006; 91: 1234-1240.
17. Barille S, Bataille R, Rapp MJ, Harousseau JL, Amiot M. Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. J Immunol 1999; 163: 5723-5728.
18. Jego G, Bataille R, Pellat-Deceunynck C. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood 2001; 97: 1817-1822.
19. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296 550-553.
20. Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 2003; 116: 2987-2998.
21. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003; 100: 183-188.
22. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999; 344 (Part 2): 305-311.
23. Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA et al. Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst 2002; 94: 522-528.
24. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006; 12: 11-19.
25. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277: 3247-3257.
26. Li F, Yang J, Ramnath N, Javle MM, Tan D. Nuclear or cytoplasmic expression of survivin: What is the significance? Intl Cancer 2005; 114: 509-512.
27. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96: 1921-1925.
28. Martinez A, Bellosillo B, Bosch F, Ferrer A, Marce S, Villamor N et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 2004; 164: 501-510.
29. Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, Rousselot P et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 2000; 111: 196-203.
30. Nakagawa Y, Abe S, Kurata M, Hasegawa M, Yamamoto K, Inoue M et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Haematol 2006; 81: 824-831.
31. Conway EM, Pollefeyt S, Steiner-Mosonyi M, Luo W, Devriese A, Lupu F et al. Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. Gastroenterology 2002; 123: 619-631.
32. Salvesen GS, Duckett CS. IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3: 401-410.
33. Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-incluced apoptosis. J Biol Chem 2003; 278: 23130-23140.
34. Liu T, Brouha B, Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene 2004; 23: 39-48.
35. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004; 114: 1117-1127.
36. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 2001; 98: 635-640.
37. Fukuda S, Pelus LM. Elevation of Survivin levels by hematopoietic growth factors occurs in quiescent CD34+ hematopoietic stem and progenitor cells before cell cycle entry. Cell Cycle 2002; 1: 322-326.
38. Suzuki A, Hayashida M, Ito T, Kawano H, Nakano T, Miura M et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene 2000; 19: 3225-3234.
39. Mazars GR, Portier M, Zhang XG, Jourdan M, Bataille R, Theillet C et al. Mutations of the p53 gene in human myeloma cell lines. Oncogene 1992; 7: 1015-1018.
40. Beltrami E, Plescia J, Wilkinson JC, Duckett CS, Altieri DC. Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J Biol Chem 2004; 279 2077-2084.
41. Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA 2004; 101: 15100-15105.